ETF Daily News16 天
BioAtla (NASDAQ:BCAB) Shares Down 6.1% – Time to Sell?
BioAtla, Inc. (NASDAQ:BCAB – Get Free Report) shares traded down 6.1% during trading on Monday .The stock traded as low as $0.48 and last traded at $0.50. 1,421,670 shares changed hands during ...
Yahoo Finance26 天
BioAtla, Inc. (BCAB)
Presentation Details: Title:Phase 2 trial of ozuriftamab vedotin (BA3021), a SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company ...
Pharmaceutical Technology1 个月
Evalstotug by BioAtla for Gastric Cancer: Likelihood of Approval
The company’s pipeline products candidate includes BA3011 (mecbotamab vedotin) targets undifferentiated pleomorphic sarcoma, non-small cell lung cancer; BA3021 (ozuriftamab vedotin) for melanoma, ...
Pharmaceutical Technology1 个月
Evalstotug by BioAtla for Solid Tumor: Likelihood of Approval
The company’s pipeline products candidate includes BA3011 (mecbotamab vedotin) targets undifferentiated pleomorphic sarcoma, non-small cell lung cancer; BA3021 (ozuriftamab vedotin) for melanoma, ...
英为财情1 个月
Bioatla现在的股价报0.604
Bioatla的股票在纳斯达克挂牌交易。 Bioatla的股票代码是什么？ Bioatla的股票代码是“BCAB。” Bioatla的市值是多少？ 截至今天，Bioatla的市值是29.10M。 Bioatla的每股收益(EPS)是多少？ Bioatla的每股收益(EPS)是-1.70。 Bioatla的下一财报日是哪天？ Bioatla会在2025年3月19日公布 ...
The Globe and Mail1 个月
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical ...
mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate ...
Investing1 个月
BioAtla's SWOT analysis: oncology biotech stock faces pivotal year
Mecbotamab vedotin has demonstrated encouraging efficacy in KRAS mutant non-small cell lung ... The company is reportedly in discussions for both Evalstotug and Ozuriftamab, exploring opportunities ...